Drug Search Results
More Filters [+]

MK-3281

Alternative Names: mk-3281, mk3281, mk 3281
Latest Update: 2018-09-05
Latest Update Note: Clinical Trial Update

Product Description

Merck was developing mk-3281, an oral HCV-NS5B Inhibitor for Hepatitis C. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00635804)

Mechanisms of Action: HCV-NS5B Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-3281

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hepatitis A|Hepatitis C

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-3281-002

P1

Completed

Hepatitis C|Hepatitis A

2009-12-22

Recent News Events

Date

Type

Title